Add to a list

Inactive Instrument

Biocorrx Inc Share Price Other OTC

US09073C1062

Healthcare Facilities & Services

on all subscriptions*

Last hours

Enjoy this offer

* See conditions under "Our services"

BioCorRx Inc. is an addiction treatment solutions company. The Company is engaged in offering treatment for substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app, along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight-loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. It also controls BioCorRx Pharmaceuticals Inc., a clinical-stage drug development subsidiary, which is seeking FDA approval for BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.

Employees

Sector

Healthcare Facilities & Services

More about the company

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

Market Cap	95.88L 83.54L 77.01L 72.44L 1.36Cr 90Cr 1.36Cr 9.16Cr 3.56Cr 45Cr 3.6Cr 3.52Cr 154.35Cr	P/E 2024	-0.78x	P/E 2025	-1.56x
Enterprise Value	1.16Cr 1.01Cr 93.09L 87.56L 1.64Cr 109.23Cr 1.65Cr 11Cr 4.3Cr 54Cr 4.35Cr 4.26Cr 186.57Cr	EV / Sales 2024	1,004x	EV / Sales 2025	11.4x
Free-Float	38.64%	Yield 2024 *	-	Yield 2025	-

15/05	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
01/04	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
31/03	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	CI
06/01	BioCorRx Inc. Announces Board Changes, Effective January 1, 2026	CI
15/11	BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/25/14	BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
29/25/29	BioCorRx Inc. announced that it has received $0.35 million in funding	CI
16/25/16	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
01/25/01	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
31/25/31	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	CI
14/24/14	BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
14/24/14	BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
15/24/15	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

10/12	BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th	AQ
15/24/15	BioCorRx Reports Business Update for the Second Quarter of 2024	AQ
16/24/16	BioCorRx Reports Business Update for the First Quarter of 2024	AQ
03/24/03	BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia	AQ
02/24/02	BioCorRx Reports Business Update for 2023	AQ

Manager	Title	Age	Since
Lourdes Felix CEO	Chief Executive Officer	58	09/11/2020
Louis Lucido PSD	President	77	05/01/2024

Director	Title	Age	Since
Lourdes Felix BRD	Director/Board Member	58	07/03/2013
Kent Emry CHM	Chairman	57	-
Louis Lucido BRD	Director/Board Member	77	01/03/2019

Biocorrx Inc Share Price Other OTC

Stocks

US09073C1062

Healthcare Facilities & Services

Valuation: Biocorrx Inc

Latest news : Biocorrx Inc

Press Releases: Biocorrx Inc

Quotes and Performance

Managers and Directors: Biocorrx Inc

Other Healthcare Facilities & Services

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOCORRX INC	-15.84%	+6.09%	-	-	95.88L
CVS HEALTH CORPORATION	-0.85%	-2.15%	+47.10%	+45.19%	13TCr
HCA HEALTHCARE, INC.	-3.35%	-0.88%	-0.45%	+29.33%	8.32TCr
FRESENIUS SE & CO. KGAA	+0.73%	+5.36%	-4.66%	+55.71%	2.54TCr
QUEST DIAGNOSTICS INCORPORATED	-1.40%	-4.33%	+8.47%	+40.69%	2.16TCr
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+0.05%	+2.59%	-9.12%	-22.77%	2.03TCr
TENET HEALTHCARE CORPORATION	-3.32%	-0.35%	+2.98%	+120.03%	1.49TCr
REDE D'OR SÃO LUIZ S.A.	-0.66%	-3.02%	-5.03%	-1.20%	1.41TCr
DAVITA INC.	+0.47%	+2.00%	+53.11%	+112.98%	1.33TCr
FRESENIUS MEDICAL CARE AG	-1.05%	+3.20%	-11.19%	-4.66%	1.27TCr
Average	-2.67%	+0.78%	+9.02%	+41.70%	3.68TCr
Weighted average by Cap.	-1.45%	-0.50%	+19.00%	+39.74%

	2024	2025
Net sales	7.66T 6.68T 6.16T 5.79T 10.83T 7L 10.91T 73.25T 28.45T 4L 28.77T 28.15T 12.34L	8L 7L 6L 6L 11.27L 7.51Cr 11.35L 76.18L 29.59L 3.7Cr 29.92L 29.28L 13Cr
Net income	-51.06L -44.49L -41.01L -38.58L -72.17L -48Cr -72.68L -4.88Cr -1.89Cr -24Cr -1.92Cr -1.88Cr -82Cr	-34.4L -29.97L -27.63L -25.99L -48.62L -32Cr -48.96L -3.29Cr -1.28Cr -16Cr -1.29Cr -1.26Cr -55Cr
Net Debt	27.18L 23.68L 21.83L 20.54L 38.42L 26Cr 38.69L 2.6Cr 1.01Cr 13Cr 1.02Cr 99.85L 44Cr	20.01L 17.44L 16.07L 15.12L 28.29L 19Cr 28.49L 1.91Cr 74.27L 9.3Cr 75.12L 73.51L 32Cr